High incidence of MGMT and RARβ promoter methylation in primary glioblastomas: Association with histopathological characteristics, inflammatory mediators and clinical outcome

Molecular Medicine

Volumn 16, Issue 1-2, 2010, Pages 1-9

  Piperi, Christina ^a   Themistocleous, Marios S ^b   Papavassiliou, George A ^c   Farmaki, Elena ^a   Levidou, Georgia ^b   Korkolopoulou, Penelope ^b   Adamopoulos, Christos ^a   Papavassiliou, Athanasios G ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c 'Laiko' General Hospital ^*

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; INTERLEUKIN 6; INTERLEUKIN 8; PROSTAGLANDIN SYNTHASE; VASCULOTROPIN;

ARTICLE; ASTROCYTOMA; CANCER GRADING; CDH13 GENE; CLINICAL ARTICLE; CONTROLLED STUDY; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; METHYLATION; MGMT GENE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAR BETA GENE; RASSF1A GENE; TUMOR GENE;

ADULT; AGED; ANGIOGENIC PROTEINS; BRAIN NEOPLASMS; CADHERINS; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION MEDIATORS; INTERLEUKINS; MALE; MIDDLE AGED; PROGNOSIS; PROMOTER REGIONS, GENETIC; RECEPTORS, RETINOIC ACID; TUMOR SUPPRESSOR PROTEINS;

EID: 73949090337     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2009.00140     Document Type: Article

References (46)

1. Hsieh JC, Lesniak MS. (2005) Surgical management of high-grade gliomas. Expert Rev. Neurother. 5:33-9.
2. Maher EA, et al. (2001) Malignant glioma: genetics and biology of a grave matter. Genes. Dev. 15:1311-33.
3. Cavenee WK, et al. (2000) Diffusely infiltrating astrocytomas. In: Pathology and Genetics of Tumours of the Nervous System. 2nd ed. Kleihues P, Cavenee WK (eds.) IARC Press, Lyon. pp. 10-21.
4. Burger PC, Green SB. (1987) Patient age, histologic features, and length of survival in patients with glioblastoma multiforme. Cancer. 59:1617-25.
5. Esteller M. (2002) CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene. 21:5427-40.
6. Jones PA, et al. (2002) The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3:415-28.
7. Esteller M. (2003) Relevance of DNA methylation in the management of cancer. Lancet Oncol. 4:351-8.
8. Dammann R, et al. (2000) Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat. Genet. 25:315-9.
9. Agathanggelou A, et al. (2001) Methylation associated inactivation of RASSF1Afrom region 3p21.3 in lung, breast and ovarian tumours. Oncogene. 20:1509-18.
10. Morrissey C, et al. (2001) Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma. Cancer Res. 61:7277-81.
11. Lorente A, et al. (2009) RASSF1A, BLU, NORE1A, PTEN and MGMT expression and promoter methylation in gliomas and glioma cell lines and evidence of deregulated expression of de novo DNMTs. Brain Pathol. 19:279-92.
12. Soprano DR, Qin P, Soprano KJ. (2004) Retinoic acid receptors and cancers. Annu. Rev. Nutr. 24:201-24.
13. Losi-Guembarovski R, Kuasne H, Guembarovski AL, Rainho CA, Cólus IM. (2007) DNA methylation patterns of the CDH1, RARB, and SFN genes in choroid plexus tumors. Cancer Genet. Cytogenet. 179:140-5.
14. Michalowski MB, et al. (2006) Methylation of RASSF1A and TRAIL pathway-related genes is frequent in childhood intracranial ependymomas and benign choroid plexus papilloma. Cancer Genet. Cytogenet. 166:74-81.
15. Lee SW. (1996) H-cadherin, a novel cadherin with growth inhibitory functions and diminished expression in human breast cancer. Nat. Med. 2:776-82.
16. Toyooka KO, et al. (2001) Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer Res. 61:4556-60.
17. Toyooka S, et al. (2002) Aberrant methylation of the CDH13 (H-cadherin) promoter region in colorectal cancers and adenomas. Cancer Res. 62:3382-86.
18. Yu J, et al. (2004) Methylation profiles of thirty four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma. BMC Cancer. 4:65.
19. Pegg AE. (2000) Repair of O(6)-alkylguanine by alkyltransferases. Mutat. Res. 462:83-100.
20. Paz MF, et al. (2004) CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin. Cancer Res. 10:4933-8.
21. 6-methylguanine-DNA methyltransferase methylation and TP53 mutation in malignant astrocytomas and their relationships with clinical course. Int. J. Cancer 113:581-7.
22. Gorlia T, et al. (2008) Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol. 9:29-38.
23. Samaras V, et al. (2007) Application of the ELISPOT method for comparative analysis of interleukin (IL)-6 and IL-10 secretion in peripheral blood of patients with astroglial tumors. Mol. Cell Biochem. 304:343-51.
24. Brat DJ, Bellail AC, Van Meir EG. (2005) The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro. Oncol. 7:122-33.
25. Wenger RH, Gassmann M. (1997) Oxygen(es) and the hypoxia-inducible factor-1. Biol. Chem. 378:609-16.
26. Korkolopoulou P, et al. (2004) Hypoxia-inducible factor 1alpha/vascular endothelial growth factor axis in astrocytomas. Associations with microvessel morphometry, proliferation and prognosis. Neuropathol. Appl. Neurobiol. 30:267-78.
27. Perdiki M, et al. (2007) Cyclooxygenase-2 expression in astrocytomas. Relationship with microvascular parameters, angiogenic factors expression and survival. Mol. Cell. Biochem. 295:75-83.
28. Samaras V, et al. (2009) Analysis of interleukin (IL)-8 expression in human astrocytomas: associations with IL-6, cyclooxygenase-2, vascular endothelial growth factor, and microvessel morphometry. Hum. Immunol. 70:391-7.
29. Louis DN, et al. (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114:97-109.
30. Jesien-Lewandowicz E, et al. (2009) High incidence of MGMT promoter methylation in primary glioblastomas without correlation with TP53 gene mutations. Cancer Genet. Cytogenet. 188:77-82.
31. Nakamura M, Watanabe T, Yonekawa Y, Kleihues P, Ohgaki H. (2001) Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C → A:T mutations of the TP53 tumor suppressor gene. Carcinogenesis. 22:1715-9.
32. Hegi ME, et al. (2004) Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin. Cancer Res. 10:1871-4.
33. Krex D, et al. (2007) Long-term survival with glioblastoma multiforme. Brain 130:2596-606.
34. 6-methylguanine-DNA methyltransferase and mismatch repair protein status in human gallbladder carcinoma. Int. J. Mol. Med. 11:65-9.
35. - human tumor cell strains. Carcinogenesis. 4:199-205.
36. Dolan ME, Pegg AE. (1997) O6-benzylguanine and its role in chemotherapy. Clin. Cancer Res. 3:837-47.
37. Klein O, Grignon Y, Civit T, Auque J, Marchal JC. (2005) Methylation status of RARbeta gene promoter in low and high grade cerebral glioma. Comparison with normal tissue. Immuno-histochemical study of nuclear RARbeta expression in low and high grade cerebral glioma cells. Comparison with normal cells. 48 tumors. Neurochirurgie. 51:147-54.
38. Gao Y, et al. (2004) Hypermethylation of the RASSF1A gene in gliomas. Clin. Chim Acta. 349:173-9.
39. Girault I, Tozlu S, Lidereau R, Bieche I. (2003) Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas. Clin. Cancer Res. 9:4415-22.
40. Azarschab P, et al. (2003) Epigenetic control of E-cadherin (CDH1) by CpG methylation in metastasising laryngeal cancer. Oncol. Rep. 10:501-3.
41. Ushijima T, Okochi-Takada E. (2005) Aberrant methylations in cancer cells: where do they come from? Cancer Sci. 96:206-11.
42. Hodge DR, et al. (2001) Interleukin-6 regulation of the human DNA methyltransferase (HDNMT) gene in human erythroleukemia cells. J. Biol. Chem. 276:39508-11.
43. Hodge DR, Li D, Qi SM, Farrar WL. (2002) IL-6 induces expression of the Fli-1 proto-oncogene via STAT3. Biochem. Biophys. Res. Commun. 292:287-91.
44. Van Meir EG, et al. (1992) Interleukin-8 is produced in neoplastic and infectious diseases of the human central nervous system. Cancer Res. 52:4297-305.
45. Tang LP, et al. (2006) An inverse correlation between interleukin-6 and select gene promoter methylation in patients with gastric cancer. Digestion. 74:85-90.
46. Makar KW, Wilson CB. (2004) DNA methylation is a nonredundant repressor of the Th2 effector program. J. Immunol. 173:4402-6.